Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsSecurities - TradableShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Current Deferred Revenue: 2022-2024

Historic Current Deferred Revenue for Praxis Precision Medicines (PRAX) over the last 2 years, with Sep 2024 value amounting to $1.2 million.

  • Praxis Precision Medicines' Current Deferred Revenue fell 24.61% to $1.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.2 million, marking a year-over-year decrease of 24.61%. This contributed to the annual value of $1.4 million for FY2023, which is 50.60% down from last year.
  • Latest data reveals that Praxis Precision Medicines reported Current Deferred Revenue of $1.2 million as of Q3 2024, which was down 0.51% from $1.2 million recorded in Q2 2024.
  • Praxis Precision Medicines' Current Deferred Revenue's 5-year high stood at $2.8 million during Q4 2022, with a 5-year trough of $1.2 million in Q3 2024.
  • Over the past 3 years, Praxis Precision Medicines' median Current Deferred Revenue value was $1.5 million (recorded in 2023), while the average stood at $1.7 million.
  • Data for Praxis Precision Medicines' Current Deferred Revenue shows a maximum YoY crashed of 50.61% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Praxis Precision Medicines' Current Deferred Revenue stood at $2.8 million in 2022, then crashed by 50.60% to $1.4 million in 2023, then decreased by 24.61% to $1.2 million in 2024.
  • Its last three reported values are $1.2 million in Q3 2024, $1.2 million for Q2 2024, and $1.3 million during Q1 2024.